Holen Sie sich die Stockscreener-App
33.47
1.24%
0.41
Handel nachbörslich:
33.47
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Why Spyre Therapeutics Inc. stock remains resilient2025 Trading Volume Trends & AI Driven Price Predictions - Улправда
Will Spyre Therapeutics Inc. stock deliver shareholder valueMarket Risk Summary & Precise Swing Trade Alerts - Улправда
Mizuho Initiates Spyre Therapeutics at Outperform With $53 Price Target - marketscreener.com
Mizuho Initiates Coverage on Spyre Therapeutics (SYRE) with 'Out - GuruFocus
Mizuho initiates Spyre Therapeutics stock with Outperform rating By Investing.com - Investing.com UK
SYRE: Citigroup Initiates Coverage with a 'Buy' Rating and $64 P - GuruFocus
Citigroup Initiates Spyre Therapeutics at Buy With $64 Price Target - marketscreener.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
60,372,927 Common Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain Series A Preferred Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain Series B Preferred Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Spyre Therapeutics stock hits 52-week high at 35.0 USD By Investing.com - Investing.com Canada
Spyre Therapeutics stock hits 52-week high at 35.0 USD - Investing.com
Spyre Therapeutics (SYRE): Assessing Valuation After a Sharp Momentum-Driven Share Price Surge - Yahoo Finance
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week HighShould You Buy? - MarketBeat
A Short Squeeze Could Send This Little-Known Biotech Stock Soaring - inkl
Affinity Asset Advisors LLC Raises Stock Holdings in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics (NASDAQ: SYRE) issues 20,300-share inducement stock options - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares - MarketBeat
Will Spyre Therapeutics Inc. (3920) stock see insider accumulationEarnings Overview Report & Fast Momentum Stock Entry Tips - Newser
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 7.2%Still a Buy? - MarketBeat
Spyre Therapeutics CEO Turtle Cameron sells $435k in stock By Investing.com - Investing.com UK
Spyre Therapeutics: A New Era Unfolds? - timothysykes.com
A significant driver of top-line growth: Spyre Therapeutics Inc (SYRE) - setenews.com
Spyre Therapeutics stock reaches 52-week high at 30.56 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics stock reaches 52-week high at 30.56 USD - Investing.com
Is Spyre Therapeutics Inc. (3920) stock at risk of policy regulation2025 Valuation Update & Fast Exit and Entry Trade Guides - Newser
Why Spyre Therapeutics Inc. stock is in analyst buy zone2025 AllTime Highs & Detailed Earnings Play Strategies - Newser
Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month High on Analyst Upgrade - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Jones Trading to Buy Rating - MarketBeat
What is the fair value of Spyre Therapeutics Inc. stock nowRate Hike & Verified Momentum Stock Watchlist - Newser
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Jones Trading to “Buy” Rating - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Sets New 52-Week High After Analyst Upgrade - Defense World
Can Spyre Therapeutics Inc. stock deliver consistent earnings growthMarket Performance Summary & Risk Controlled Swing Alerts - Newser
Jones Trading Upgrades Spyre Therapeutics (SYRE) - Nasdaq
SYRE Stock Upgraded by Jones Trading; New Price Target Set at $6 - GuruFocus
Spyre Therapeutics, Inc. $SYRE Shares Acquired by Franklin Resources Inc. - MarketBeat
Spyre Therapeutics, Inc. $SYRE Shares Purchased by Intech Investment Management LLC - Defense World
Spyre Therapeutics, Inc. $SYRE Shares Purchased by Geode Capital Management LLC - MarketBeat
Spyre stock rating upgraded to Buy at Jones Trading on TL1A blockade potential - Investing.com Canada
Nasdaq Composite Tracks Rising Biotech Momentum At Spyre Therapeutics - Kalkine Media
What analysts say about Spyre Therapeutics Inc 3920 stockFundamental Stock Analysis & Big Returns Low Cost - earlytimes.in
Spyre Therapeutics, Inc. $SYRE Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
A Look at Spyre Therapeutics Inc (SYRE) Shares in the Recent Past Indicates Growth - Setenews
Spyre Therapeutics stock hits 52-week high at 29.1 USD By Investing.com - Investing.com South Africa
Spyre Therapeutics stock hits 52-week high at 29.1 USD - Investing.com India
Why Spyre Therapeutics Inc. (3920) stock benefits from AI revolutionWeekly Market Outlook & Weekly Stock Performance Updates - newser.com
Can Spyre Therapeutics Inc. stock deliver strong Q4 earningsMarket Movers & Fast Entry High Yield Tips - newser.com
Is Spyre Therapeutics Inc. (3920) stock worth buying before Fed actionTrend Reversal & Daily Stock Momentum Reports - newser.com
Top investors say Spyre Therapeutics Inc (SYRE) ticks everything they need - Setenews
0.31%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):